Gene Expression Changes Associated with Resistance to Intravenous Corticosteroid Therapy in Children with Severe Ulcerative Colitis

Boyko Kabakchiev, Dan Turner, Jeffrey S. Hyams, David Mack, Neal S. LeLeiko, Wallace Crandall, James Markowitz, Anthony Otley, Wei Xu, Pingzhao Hu, Anne M. Griffiths, Mark S. SilverbergPLoS 2010 · DOI

Abstract

Elevated expression of several genes involved in inflammatory pathways was associated with resistance to intravenous corticosteroid therapy early in the course of treatment. Gene expression profiles may be useful to classify resistance to intravenous corticosteroids in children with severe UC and assist with clinical management decisions.

Introduction

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by mucosal inflammation. For pediatric patients hospitalized with a severe flare-up, intravenous corticosteroid (IVCS) therapy is the standard first-line treatment. However, approximately 29% of these patients exhibit steroid resistance. The clinical challenge lies in the timely identification of non-responders; prolonged ineffective steroid treatment increases the risk of toxicity and delays necessary interventions such as second-line medical therapies (e.g., infliximab) or colectomy. While the Pediatric UC Activity Index (PUCAI) provides clinical guidance, it relies on symptomatic changes that may take several days to manifest. This study investigates whether a molecular "snapshot"—specifically a gene expression profile in the blood—can identify non-responders early in the treatment course.

Methodology

The researchers employed a nested case-control design within the prospective OSCI study, which included 128 pediatric patients (ages 2-18) hospitalized for severe UC across multiple centers in North America and Israel. From this cohort, a discovery set of 20 "responders" and 20 "non-responders" was selected based on clinical status by Day 5 of treatment.

Total RNA was extracted from whole blood collected on Day 3 of IVCS therapy. Gene expression was quantified using Affymetrix Human Gene 1.0 ST arrays, covering over 28,000 genes. The "local-pooled error" (LPE) method was used to identify differentially expressed genes, a robust approach for smaller sample sizes. Findings were validated using RT-PCR for seven key genes. To develop a predictive model, the researchers used Prediction Analysis for Microarrays (PAM) with a "shrunken centroid" method to identify the minimal gene set required for accurate patient classification. The microarray data is publicly available in the NCBI Gene Expression Omnibus (GEO) under series record GSE21231.

Results

The analysis identified 41 genes significantly differentially expressed between responders and non-responders. Notable genes such as OLFM4 and MMP8 showed nearly double the expression levels in non-responders compared to responders.

A refined 10-gene signature (RAP1GAP, CD177, ELOVL7, CLIC2, TSTA3, HP, MMP8, NECAB1, PROS1, ITGB3) was developed. This molecular signature demonstrated the ability to classify patients with 80% sensitivity and 80% specificity. Technical validation using RT-PCR showed a high correlation with the microarray data, confirming the reliability of the transcriptomic measurements.

Discussion

Network analysis revealed that many over-expressed genes in non-responders, including CEACAM1 and MMP8, are linked to the Interleukin-8 (IL8) pathway. While corticosteroids typically inhibit IL8, the elevated levels of downstream genes in non-responders suggest a failure of the steroid-mediated "brake" on the inflammatory system. Additionally, the study identified ABCC4 (MRP4), a member of the multi-drug resistance superfamily, as a novel candidate for steroid resistance, suggesting that active drug efflux may play a role in treatment failure.

A significant practical finding is that these molecular signals are detectable in whole blood, offering a less invasive alternative to traditional colonoscopy and biopsy. Furthermore, identifying this signature on Day 3 provides a two-to-four-day clinical head start compared to standard decision-making timelines (typically Day 5-7).

Conclusion and Future Directions

While promising, this study's discovery phase involved a relatively small group of 40 patients, necessitating validation in larger, independent prospective cohorts. Current sampling occurred on Day 3 post-treatment; future research should investigate pre-treatment (Day 0) biomarkers to predict resistance before therapy initiation. It also remains to be determined if this 10-gene signature is specific to UC or represents a general mechanism of corticosteroid resistance. Transitioning from microarray analysis to a rapid, bedside PCR-based test for these 10 genes is the next step toward clinical implementation.

Summary updated

Abstract

Elevated expression of several genes involved in inflammatory pathways was associated with resistance to intravenous corticosteroid therapy early in the course of treatment. Gene expression profiles may be useful to classify resistance to intravenous corticosteroids in children with severe UC and assist with clinical management decisions.
BibTeX
@inproceedings{kabakchiev2010gene,
  author = {Boyko Kabakchiev and Dan Turner and Jeffrey S. Hyams and David Mack and Neal S. LeLeiko and Wallace Crandall and James Markowitz and Anthony Otley and Wei Xu and Pingzhao Hu and Anne M. Griffiths and Mark S. Silverberg},
  title = {{Gene Expression Changes Associated with Resistance to Intravenous Corticosteroid Therapy in Children with Severe Ulcerative Colitis}},
  booktitle = {PLoS},
  year = {2010},
  doi = {10.1371/journal.pone.0013085},
}
Figure